Correct. It will now be on a percentage of completion basis with the adjustment going forward. I think that probably emanates in that significant work is part of the "process/development" work and not just the manufacturing of the product. It will be good in that CDMO will show the adjustments between the accounting methodologies.
Think about it, we now have a earnings call talking about revenue recognition and the size of the potential market. Quite the change.
Also like how they even mentioned the financial capacity of Oncologie and when we will get the first tranche of payments. That should soothe the naysayers.
The old accounting system led to "lumpiness" in the Avid quarter to quarter earnings and associated "lumpiness" in the share price. The new method should smooth things out.